190 related articles for article (PubMed ID: 16755148)
21. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
[TBL] [Abstract][Full Text] [Related]
22. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
23. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
[TBL] [Abstract][Full Text] [Related]
24. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
Banasiak W; Wilkins A; Pociupany R; Ponikowski P
Kardiol Pol; 2008 Jun; 66(6):642-9; discussion 650. PubMed ID: 18626833
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period.
Formica RN; Friedman AL; Lorber MI; Bia MJ
Transplant Proc; 2004 Nov; 36(9):2675-8. PubMed ID: 15621121
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users.
de Jong HJ; Vandebriel RJ; Saldi SR; van Dijk L; van Loveren H; Cohen Tervaert JW; Klungel OH
Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):835-43. PubMed ID: 22674737
[TBL] [Abstract][Full Text] [Related]
28. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
29. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system.
Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H
Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883
[TBL] [Abstract][Full Text] [Related]
30. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
Kheterpal S; Khodaparast O; Shanks A; O'Reilly M; Tremper KK
J Cardiothorac Vasc Anesth; 2008 Apr; 22(2):180-6. PubMed ID: 18375317
[TBL] [Abstract][Full Text] [Related]
31. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
32. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
33. Effects of combined treatment with angiotensin II type 1 receptor blocker and statin on stent restenosis.
Yoshikawa M; Nakamura K; Nagase S; Sakuragi S; Kusano KF; Matsubara H; Ohe T
J Cardiovasc Pharmacol; 2009 Feb; 53(2):179-86. PubMed ID: 19188828
[TBL] [Abstract][Full Text] [Related]
34. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
35. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.
Orlić L; Mikolasević I; Sladoje-Martinović B; Bubić I; Pavletić-Persić M; Racki S
Coll Antropol; 2013 Sep; 37(3):809-14. PubMed ID: 24308221
[TBL] [Abstract][Full Text] [Related]
36. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
37. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
38. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
39. Coronary collateral circulation is less developed when ischaemic heart disease coexists with diabetes.
Rzeczuch K; Jagielski D; Kołodziej A; Kaczmarek A; Mielnik M; Banasiak W; Ponikowski P
Kardiol Pol; 2003 Feb; 58(2):85-92. PubMed ID: 14504633
[TBL] [Abstract][Full Text] [Related]
40. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
